ArticleFrontiers in immunology2024
Targeting liver cancer stem cells: the prognostic significance of MRPL17 in immunotherapy response.
Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- PSMD4 promotes malignant phenotypes and is associated with angiogenesis-related signaling and immune remodeling in hepatocellular carcinoma.Discover oncology · 2026Article
- Leveraging a disulfidptosis-based signature to characterize heterogeneity and optimize treatment in multiple myeloma.Frontiers in immunology · 2025Article
- The Role of MAPK12 in Prognosis of Patients With Liver Cancer and Effects on Stemness Characteristics.Stem cells international · 2025Article
- The Epithelial Cell-Associated Gene PMAIP1 Serves as a Prognostic Biomarker for Lung Adenocarcinoma and Can Regulate the Stemness of Lung Cancer.Stem cells international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver hepatocellular carcinoma (LIHC) ranks as the foremost cause of cancer-related deaths worldwide, and its early detection poses considerable challenges. Current prognostic indicators, including alpha-fetoprotein, have notable limitations in their clinical utility, thereby underscoring the necessity for discovering new biomarkers to improve early diagnosis and enable personalized treatment options. Method: This investigation employed single-cell analysis techniques to identify stem cell-associated genes and assess their prognostic significance for LIHC patients, as well as the efficacy of immunotherapy, utilizing nonnegative matrix factorization (NMF) cluster analysis. A diagnostic model for LIHC was developed and validated through multiple datasets and various machine learning clustering methods. The XGBOOST algorithm identified MRPL17 as the most significant prognostic gene among those associated with stem cells. Additionally, the research explores the relationship between MRPL17 expression and immune cell infiltration. Immunofluorescence staining of LIHC tissue samples was conducted to evaluate the expression and prognostic value of MRPL17, as well as its correlation with KI67. Results: Through single-cell analysis, this study identified 14 essential stem cell-related genes, highlighting their significance in the diagnosis, prognostication, and potential treatment strategies for LIHC patients. Various machine learning algorithms indicated that MRPL17 is particularly associated with patient prognosis and responses to immunotherapy. Furthermore, experimental results demonstrate that MRPL17 is upregulated in LIHC and correlates with poor prognosis, as well as positively correlating with KI67. Conclusion: Cancer stem cells are pivotal in the mechanisms of immune evasion within the tumor microenvironment and have a substantial impact on treatment results. This study experimentally validated MRPL17 as a promising prognostic biomarker, emphasizing the need to target liver cancer stem cells to improve patient prognosis and enhance treatment effectiveness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.